In clinical trials, maximum titration doses were 40 mg/day PO ER capsules for patients weighing 75 kg or less and from 50 to 60 mg/day PO ER capsules for those weighing more than 75 kg. During clinical trials, there was not adequate evidence that doses greater than 20 mg/day conferred additional benefit in patients 13 to 17 years of age. TITRATION: Adjust upward or downward at weekly intervals if needed dose should be based on individual response and tolerability. CONVERSION FROM ANOTHER DOSAGE FORM OF AMPHETAMINES SALTS: Adolescents taking divided doses of the immediate-release formulation may be switched to the extended-release (ER) formulation once daily at the same total daily dose. May titrate to 20 mg PO once daily after 1 week if ADHD symptoms are not adequately controlled. In treatment guidelines, stimulants are considered first-line therapy in the treatment of ADHD.ДЎ0 mg PO once daily in the morning for both initial therapy and when converting to extended-release amphetamine dextroamphetamine from another stimulant medication. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. ADHD is a chronic condition that will require ongoing management and monitoring. Lack of response to one stimulant does not predict a response to other stimulants. STABILIZATION: Dose should be based on individual response and tolerability use lowest effective dose after stabilization. During adult ADHD trials, there was not adequate evidence that doses greater than 20 mg/day ER capsules conferred additional benefit during these trials, 60 mg PO once daily was the highest titration dose used.

CONVERSION FROM ANOTHER DOSAGE FORM OF AMPHETAMINES SALTS: Adults taking divided doses of the immediate-release formulation may be switched to the extended-release (ER) formulation once daily at the same total daily dose. When initiating treatment for the first time or switching from another ADHD medication, the recommended dose is 20 mg PO once daily upon awakening.

Adderall amphetamine